Cargando…
Anti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts
BACKGROUND: Intestinal fibrosis is a serious complication of inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. There is no specific treatment for intestinal fibrosis. Studies have indicated that peroxisome proliferator-activated receptor- γ (PPAR-γ) agonists have anti-fib...
Autores principales: | Koo, Jun Bon, Nam, Myeong-Ok, Jung, Younshin, Yoo, Jongman, Kim, Duk Hwan, Kim, Gwangil, Shin, Sung Jae, Lee, Kee Myung, Hahm, Ki Baik, Kim, Jong Woo, Hong, Sung Pyo, Lee, Kwang Jae, Yoo, Jun Hwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463383/ https://www.ncbi.nlm.nih.gov/pubmed/28592228 http://dx.doi.org/10.1186/s12876-017-0627-4 |
Ejemplares similares
-
Umbilical cord/placenta-derived mesenchymal stem cells inhibit fibrogenic activation in human intestinal myofibroblasts via inhibition of myocardin-related transcription factor A
por: Choi, Yoon Jeong, et al.
Publicado: (2019) -
Author Correction: Organoid-based epithelial to mesenchymal transition (OEMT) model: from an intestinal fibrosis perspective
por: Hahn, Soojung, et al.
Publicado: (2018) -
Organoid-based epithelial to mesenchymal transition (OEMT) model: from an intestinal fibrosis perspective
por: Hahn, Soojung, et al.
Publicado: (2017) -
Periodontitis is associated with an increased risk for proximal colorectal neoplasms
por: Kim, Gun Woo, et al.
Publicado: (2019) -
Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy
por: Douglass, Angela, et al.
Publicado: (2008)